PNC Financial Services Group
SYRS

PNC Financial Services Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

PNC Financial Services Group’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,095
Closed -$252 – 5029
2024
Q4 		$252 Hold
1,095
– – ﹤0.01% 4624
2024
Q3 		$2.35K Hold
1,095
– – ﹤0.01% 4259
2024
Q2 		$5.65K Hold
1,095
– – ﹤0.01% 3957
2024
Q1 		$5.86K Hold
1,095
– – ﹤0.01% 3913
2023
Q4 		$8.53K Hold
1,095
– – ﹤0.01% 3784
2023
Q3 		$4.33K Hold
1,095
– – ﹤0.01% 4026
2023
Q2 		$3.45K Hold
1,095
– – ﹤0.01% 4212
2023
Q1 		$2.92K Hold
1,095
– – ﹤0.01% 4210
2022
Q4 		$3.93K Hold
1,095
– – ﹤0.01% 4068
2022
Q3 		$7K Buy
+1,095
New +$8.9K ﹤0.01% 3893

Other funds holding SYRS

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

PNC Financial Services Group's SYRS Position: Q1 2025 in Review

PNC Financial Services Group sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 1,095 shares — an estimated $252 sold.

PNC Financial Services Group first reported a position in SYRS in Q3 2022 and held it in 10 quarters. The position peaked at $8.53K in Q4 2023. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.

  • PNC Financial Services Group reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • PNC Financial Services Group sold 1,095 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $252.
  • PNC Financial Services Group first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2022 and held it in 10 quarters.
  • PNC Financial Services Group's Syros Pharmaceuticals, Inc. Common Stock position peaked at $8.53K in Q4 2023.
  • 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on PNC Financial Services Group's 13F filing for Q1 2025, filed 9 May 2025.